VK2735 for Weight Management Phase 2 (Venture Oral Dosing)
Public ClinicalTrials.gov record NCT06828055. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Dose Finding Study of VK2735 Oral Formulation for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 Oral Formulation in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. VK2735 or matched placebo will be administered once daily.
Study identification
- NCT ID
- NCT06828055
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 280 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 17, 2024
- Primary completion
- Jun 23, 2025
- Completion
- Aug 14, 2025
- Last update posted
- Oct 5, 2025
2024 – 2025
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Viking Clinical Site #111 | Peoria | Arizona | 85381 | — |
| Viking Clinical Site #105 | Lake Forest | California | 96230 | — |
| Viking Clinical Site #101 | Clearwater | Florida | 33756 | — |
| Viking Clinical Site #108 | Largo | Florida | 33777 | — |
| Viking Clinical Site #107 | Ocoee | Florida | 34761 | — |
| Viking Clinical Site #102 | Port Orange | Florida | 32127 | — |
| Viking Clinical Site #100 | Indianapolis | Indiana | 46260 | — |
| Viking Clinical Site #110 | Louisville | Kentucky | 40213 | — |
| Viking Clinical Site #114 | Marrero | Louisiana | 70072 | — |
| Viking Clinical Site #109 | City of Saint Peters | Missouri | 63303 | — |
| Viking Clinical Site #112 | Kansas City | Missouri | 64131 | — |
| Viking Clinical Site #113 | Butte | Montana | 59701 | — |
| Viking Clinical Site #103 | Knoxville | Tennessee | 37909 | — |
| Viking Clinical Site #104 | Austin | Texas | 78705 | — |
| Viking Clinical Site #106 | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06828055, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 5, 2025 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06828055 live on ClinicalTrials.gov.